CN1557407A - Botanical medicine for preventing and treating arteriosclerosis and regulating blood fat and its processing method - Google Patents
Botanical medicine for preventing and treating arteriosclerosis and regulating blood fat and its processing method Download PDFInfo
- Publication number
- CN1557407A CN1557407A CNA2004100152299A CN200410015229A CN1557407A CN 1557407 A CN1557407 A CN 1557407A CN A2004100152299 A CNA2004100152299 A CN A2004100152299A CN 200410015229 A CN200410015229 A CN 200410015229A CN 1557407 A CN1557407 A CN 1557407A
- Authority
- CN
- China
- Prior art keywords
- preventing
- folium ginkgo
- ginkgo extract
- treating arteriosclerosis
- blood lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention is one kind of plant medicine for preventing and treating arteriosclerosis and regulating blood fat and its preparation process. The medicine consists of gingko leaf extractive 10-80 wt% and sea-buckthorn oil 10-90 wt% , and the preparation process includes adding the gingko leaf extractive directly into sea-buckthorn oil to obtain suspension and capsulizing. The present invention has the comprehensive medicinal effects of multiple components, multiple target points and several links, high and stable clinical effect, no toxic side effect and taking convenience, and may be taken regularly to preventing and treating atherosclerosis and regulate blood fat. The sea-buckthorn oil serves as both effective component and matrix, and this can ensure the purity of medicine, high curative effect, less preparation step and low cost.
Description
Technical field
The present invention relates to the senile cardiac cerebral arteriosclerosis of a kind of control and blood lipid regulation plant amedica prescription and manufacture method.
Background technology
Cardiovascular and cerebrovascular disease is human dead No.1 killer, accounts for the 34%-40% of total death toll.Atherosclerosis is the main pathological basis of cardiovascular disease, the pathogeny complexity, and the participation factor is numerous, mainly causes coronary heart disease, apoplexy, diseases such as hypertension, vascular senile dementia.Occurred many antiatherogenic medical treatment novel drugs, interventional therapy and surgical intervention new technique over nearly 20 years, but curative effect is all unsatisfactory.The situation that we face still is, the patient who suffers from atheromatosis is growing on and on, and sickness rate, disability rate, the fatality rate of the cardiovascular and cerebrovascular disease that is caused by atherosclerosis are still high, and on the rise.Scholarly forecast, if effectively do not intervene, along with the acceleration of the aging of society, cardiovascular and cerebrovascular disease will be very popular in China in the near future.Both at home and abroad the expert no longer just tends to making a definite diagnosis patient's treatment, but emphasizes the policy and the strategy of " putting prevention first and combining prevention with control ".The generation that causes cardiovascular and cerebrovascular disease, the risk factor one atherosclerotic control of development have been become important research project.Therefore, it is little to produce toxic and side effects, is convenient to take for a long time, at the medicine of preventing and treating atherosclerosis, blood lipid regulation multi-level in the incidence of atherosclerosis process, the effect of too many levels comprehensive drug, is more and more paid much attention to simultaneously.
Summary of the invention
The purpose of this invention is to provide a kind of plant amedica and method for making thereof of preventing and treating arteriosclerosis and blood lipid regulation, one of purpose is that this plant amedica has multicomponent, many target spots, the effect of too many levels comprehensive drug, for clinically provide stable, efficient, have no side effect, taking convenience, the pure Chinese medicinal preparation of preventing and treating atherosclerosis, blood lipid regulation that can take for a long time.
Two of purpose is to adopt existing therapeutical effect, and crude vegetal one Oleum Hippophae of double as substrate is the main component of medicine simultaneously again, has guaranteed pharmaceutical purity, thereby improves curative effect, reduces production process, reduces cost.Technical solution of the present invention is finished like this:
A kind of plant amedica of preventing and treating arteriosclerosis and blood lipid regulation, its composition (
W/
W):
Folium Ginkgo extract 10～80%
Oleum Hippophae 10～90%
The above Folium Ginkgo extract is the medicated powder of moisture 5-8%.
The apricot yellow ketone 20～25% of argentiferous in the Folium Ginkgo extract of the present invention, bilobalide 2～8%.
More than plant amedica of the present invention form (
W/
W) can also be:
Folium Ginkgo extract 40～70%
Oleum Hippophae 26～46%
Plant amedica composition of the present invention (
W/
W) the best is:
Folium Ginkgo extract 60%
Oleum Hippophae 40%
The present invention prevents and treats the manufacture method of the plant amedica of arteriosclerosis and blood lipid regulation, is Folium Ginkgo extract dry powder is directly joined in the Oleum Hippophae and to make suspension, makes soft capsule preparation.
Described Folium Ginkgo extract of above manufacture method of the present invention and Fructus Hippophae oil composition (
W/
W) be Folium Ginkgo extract 10～80%, Oleum Hippophae 10～90%.
Folium Ginkgo extract and Fructus Hippophae oil composition in the manufacture method of the present invention (
W/
W) be Folium Ginkgo extract 40～70%, Oleum Hippophae 40%.
The best of Folium Ginkgo extract and Oleum Hippophae composition in the manufacture method of the present invention (
W/
W) be Semen Ginkgo extrac 60%, Oleum Hippophae 40%.
The Oleum Hippophae main component of indication is a unsaturated fatty acid among the present invention, and the plain E of natural little life, can remove endovascular free radical, reach antioxidant effect, blood fat reducing, be can radioprotective in addition, and the main component ginkgetin and the bilobalide of Folium Ginkgo, have anti-preferably cardiac cerebral arteriosclerosis, blood lipid regulation, effect such as antioxidation.And Oleum Hippophae and Folium Ginkgo extract are share, its effect is assistant mutually, and synergism is obvious.
In the manufacture method of the present invention, because this therapeutical effect raw material of Oleum Hippophae is arranged, possessed simultaneously the substrate function again, thereby add conventional arts such as Polyethylene Glycol when making soft capsule in the prior art of having given up in addition, Folium Ginkgo extract is directly added in the Oleum Hippophae and make soft capsule, both guaranteed the purity of medicine, reduced the operation of pharmacy again, both guaranteed curative effect of medication, reduced cost again.
Advantage of the present invention is that this plant amedica has multicomponent, many target spots, the effect of too many levels comprehensive drug, for clinically provide stable, efficient, have no side effect, taking convenience, the prevention of arterial that can take for a long time is atherosis, the pure Chinese medicinal preparation of blood lipid regulation.And it is the crude vegetal of therapeutical effect that the present invention adopts, and can make substrate again simultaneously and use, and guarantees pharmaceutical purity, thereby guarantees curative effect, reduces production process and reduces cost.
Table 1, to hyperlipidemia model rat fat level affects (X ± SD)
Grop n dosage (g/kg) cholesterol triglyceride high density Pr low-density Pr extra-low density Pr
Normal control group 5 normal saline 65.98 ± 14.74 22.47 ± 13.00 30.05 ± 3.97 18.76 ± 9.39 17.17 ± 5.06
Experimental group 182 156.68 ± 48.13
※ ※15.99 ± 8.88 18.22 ± 12.70 85.04 ± 25.15*, 53.42 ± 30.56*
Experimental group 281 143.23 ± 66.03
※ ※20.40 ± 10.98 15.58 ± 6.07 65.73 ± 54.59*, 62.47 ± 33.05*
Model group 8 normal saline 247.56 ± 66.21
##21.14 ± 10.53 15.19 ± 6.51
#125.23 ± 58.09
##107.14 ± 51.15
##
Compare #P＜0.05 ##P＜0.001 with the normal control group;
Compare * P＜0.05 * * P＜0.01 with model control group
Table 2, blood coagulation resisting function experimentation (n=10)
Group RT (S) PT (S) TT (S) KPTT (S)
N.S 90.60 13.50 12.50 38.50
Experimental group 120.60
※19.60
※53.61
※85.67
※
Compound Salviae Miltiorrhizae 118.80
※18.96
※49.85
※81.53
※
※ and matched group be P＜0.01 relatively
※ TR: recalcification time; PT: prothrombing time; TT: clotting time; KPTT: kaolin part clotting time.
Table 3, to the influence (n=10) of parameters of left ventricular function
LVEOVM LVESVM EF SF
Medication preceding 138.7 ± 8.6 78.5 ± 13.8 45.5 ± 6.9 26.4 ± 7.5
107.6 ± *, 69.3 ± 12.6*, 59.3 ± 8.7*, 37.3 ± 5.4* after the medication
※ P＜0.05 LVESVM: not index of bunching is opened in left chamber; LVESVM: left chamber blood fraction;
EF: left chamber axle LVFS; SF: function is made in left chamber.
Table 4, to the influence of mice serum malonaldehyde (MDA) superoxide dismutase (SOD) level (X ± SD)
Group dosage (g/kg) number of animals MDA (nmol/ml) SOD (nU/ml)
Matched group normal saline 15 9.36 ± 2.21 189.6 ± 16.0
Experimental group 12 15 6.34 ± 3.08
※208.4 ± 4.3**
Experimental group 21 15 6.60 ± 3.84
※216.9 ± 2.1**
F value 4.59 (P＜0.01 4.59 (p＜0.01)
Long-term toxicity test for animals
This test is with 5,10,20 times of SD kind male and female rats that give trophophase of the safe soft capsule recommended amounts of heart and brain (1.0ml/kg b.w), and matched group gives corresponding water, record, observes final result 180 days:
1, each dosage group rat growthing development is good, compares there was no significant difference with matched group.
2, each dosage group picked-up forage volume and food utilization and matched group compare there was no significant difference.
3, final each dosage group rat hemogram compares there was no significant difference with matched group.
4, the every index of final blood biochemical is normal substantially, compares there was no significant difference with matched group.
5, each each organ coefficient of dosage group and matched group compare there was no significant difference.
6, the pathology sections observation is no abnormal.
After feeding in 180 days, detect in the index, no abnormal.
Its mouse oral acute toxicity test
Male and female mice LD50＞21.50g/kg.B.W, submitted sample belong to nontoxic level material.
The mouse bone marrow cells micronucleus test
1.25-10g/kg.B.W dosage, the micronucleus test result is negative, and somatic cell is not had mutagenesis.
The mouse sperm deformity test
2.5-10g/kg.BW dosage, the sperm malformation test result is negative, and sexual cell is not had the effect of mutation deformity.
Salmonella reversion test
0.5-5000ug/ no matter add or do not add the S9 mixture in each dosage of ware, result of the test is returned change bacterium colony number average and returned 2 times that become bacterium colony above nature, result of the test is negative, and not finding has direct or indirect mutagenic action to test strain.
Clinical data
Case is selected: this is organized 106 routine patients and all is selected from outpatient service, meter male 56 examples, women's 50 examples, age 41---68 year, average 53 years old.Cholesterol＞6.8mmol/L person's 16 examples wherein, cholesterol and triglyceride be rising person's 53 examples simultaneously, and cholesterol, triglyceride and beta lipoprotein be rising person's 37 examples simultaneously, wherein concurrent fatty liver person 37 examples, concurrent transaminase rising person 17 examples, ECG ST-T changer's 3 examples.
Therapeutic Method: experiment soft capsule, every 0.5g, each 2, every day 2 times.
Criterion of therapeutical effect: produce effects: TC descends＞20%, or TG＞decline 40%, or beta lipoprotein descends＞20%; Effectively: TC decline＞10%--20%, or TG＞decline 20%--40%, or beta lipoprotein decline＞10%--20%; Invalid: as not reach effective standard person.
Therapeutic outcome: after the treatment, routine blood test, routine urinalysis do not have significant change, and body weight all has in various degree and to descend, and blood pressure is steady, and subjective symptomss such as uncomfortable in chest, cardiopalmus, dizziness are clearly better.There are 43 routine Patients with Fatty Liver to cure.
After taking medicine according to above standard, cholesterol, triglyceride, beta lipoprotein effective percentage are respectively 94.3%, 91.1%, 78.8%, see the following form
Cholesterol (example) triglyceride (example) beta lipoprotein (example)
Produce effects 30 (28.3%) 36 (40%) 11 (29.7%)
Effective 70 (66%) 46 (51.1%) 18 (48.6%)
Invalid 6 (5.7%) 8 (8.9%) 8 (2.2%)
Total effective rate 100 (94.3%) 82 (91.1%) 29 (78.3%)
Manufacturing process of the present invention:
The Folium Ginkgo coarse powder filtered with 12 times of branches, 40% alcohol reflux in 2 hours, storE filtrate for the first time, take out medicinal residues filtered with 10 times of branches, 40% alcohol reflux in 1.5 hours, storE filtrate for the second time, take out residue filtered with 10 times of branches, 40% alcohol reflux in 1.5 hours again, storE filtrate for the third time, discard medicinal residues, take out filtrate, filtrate remerges ginkgo biloba succi three times, decompression recycling ethanol also is concentrated into the 0.5g/m crude drug and adds 95% ethanol, make the alcohol amount of containing reach 75% and leave standstill filtration in 24 hours at 4～10 ℃, the precipitation reject, filtrate be ginkgo biloba succi decompression recycling ethanol is not to there being the alcohol flavor again, concentrated solution is through the polyamide purification, thereafter at 180 ℃, reach the Folium Ginkgo extract medicated powder that 72～74 ℃ of following spray dryinges get moisture 5-8%, Folium Ginkgo extract medicated powder is joined stirring in the Oleum Hippophae again and get suspension, suspension makes soft capsule preparation by capsule machine.
Description of drawings
Fig. 1 soft capsule preparation process chart of the present invention
The specific embodiment
Folium Ginkgo extractum extraction process:
1, takes by weighing 10kg Folium Ginkgo coarse powder, add 12 times of 40% alcohol reflux 2 hours, filter the extracting solution of winning;
2, medicinal residues are added 10 times of 40% alcohol reflux 1.5 hours, filter second extracting solution;
3, medicinal residues are added 10 times of 40% alcohol reflux 1.5 hours, filter the 3rd extracting solution;
4, merge above-mentioned three extracting solution reduced-pressure backflow concentrated solutions, contain crude drug 0.5g/ml;
5, concentrated solution is added 5 times of 75% ethanol, leave standstill 24 hours (4-10 ℃) and filter, get supernatant, abandon precipitate;
6, the supernatant reduced-pressure backflow is not distinguished the flavor of to there being ethanol;
7, concentrated solution is crossed the active ingredient of polyamide purification;
8, the dry extract that gets moisture 5～8% after the extracting solution spray drying behind the purification is standby.
Dry extract and Oleum Hippophae are made into suspension in proportion:
Embodiment 1
Folium Ginkgo dry extract and Oleum Hippophae are mixed and made into suspension by 1: 1 part by weight, make soft capsule preparation.
Embodiment 2
With Folium Ginkgo dry extract and husky thorn oil is that 2: 1 amount is mixed by weight, makes suspension, makes soft capsule.
Embodiment 3
With Folium Ginkgo dry extract and husky thorn oil is that 3: 2 amount is mixed and made into suspension by weight, makes soft capsule.
Claims (9)
1, a kind of plant amedica of preventing and treating arteriosclerosis and blood lipid regulation, its composition (
w/
w):
Folium Ginkgo extract 10～80%
Oleum Hippophae 10～90%
2, a kind of plant amedica of preventing and treating arteriosclerosis and blood lipid regulation according to claim 1, the Folium Ginkgo extract that it is characterized in that indication is moisture 5-8% medicated powder.
3, a kind of plant amedica of preventing and treating arteriosclerosis and blood lipid regulation according to claim 1 and 2 is characterized in that the apricot yellow ketone 20～25% of Folium Ginkgo extract argentiferous, bilobalide 2～8%.
4, a kind of plant amedica of preventing and treating arteriosclerosis and blood lipid regulation according to claim 1, it is characterized in that its composition (
w/
w) be
Folium Ginkgo extract 40～70%
Oleum Hippophae 26～46%
5, a kind of plant amedica of preventing and treating arteriosclerosis and blood lipid regulation according to claim 4, it is characterized in that its composition (
w/
w) be
Folium Ginkgo extract 60%
Oleum Hippophae 40%
6, a kind of plant amedica manufacture method of preventing and treating arteriosclerosis and blood lipid regulation is characterized in that at normal temperatures Folium Ginkgo extract medicated powder directly being joined in the Oleum Hippophae and makes suspension, makes soft capsule.
7, a kind of plant amedica manufacture method of preventing and treating arteriosclerosis and blood lipid regulation according to claim 6, it is characterized in that Folium Ginkgo extract and Fructus Hippophae oil composition (
w/
w), Folium Ginkgo extract 10～80%, Oleum Hippophae 10～90%.
8, a kind of plant amedica manufacture method of preventing and treating arteriosclerosis and blood lipid regulation according to claim 7, it is characterized in that Folium Ginkgo extract and Fructus Hippophae oil composition (
w/
w), be Folium Ginkgo extract 40～70%, Oleum Hippophae 40%.
9, a kind of plant amedica manufacture method of preventing and treating arteriosclerosis and blood lipid regulation according to claim 8, it is characterized in that Folium Ginkgo extract and Fructus Hippophae oil composition (
w/
w), Folium Ginkgo extract 60%, Oleum Hippophae 40%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100152299A CN100384437C (en) | 2004-01-19 | 2004-01-19 | Botanical medicine for preventing and treating arteriosclerosis and regulating blood fat and its processing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100152299A CN100384437C (en) | 2004-01-19 | 2004-01-19 | Botanical medicine for preventing and treating arteriosclerosis and regulating blood fat and its processing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1557407A true CN1557407A (en) | 2004-12-29 |
| CN100384437C CN100384437C (en) | 2008-04-30 |
Family
ID=34351374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100152299A Expired - Fee Related CN100384437C (en) | 2004-01-19 | 2004-01-19 | Botanical medicine for preventing and treating arteriosclerosis and regulating blood fat and its processing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100384437C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102429223A (en) * | 2011-11-11 | 2012-05-02 | 完美（中国）有限公司 | Health care food with assistant blood fat reducing function and preparation method thereof |
-
2004
- 2004-01-19 CN CNB2004100152299A patent/CN100384437C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102429223A (en) * | 2011-11-11 | 2012-05-02 | 完美（中国）有限公司 | Health care food with assistant blood fat reducing function and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100384437C (en) | 2008-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1257724C (en) | Composition for preventing and treating diabets mellitus | |
| CN1301666C (en) | Health food capable of raising immunity and its production process | |
| CN1304039C (en) | Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use | |
| CN1253159C (en) | Health product of compound propolis and preparing method | |
| CN1679706A (en) | Medicinal preparation containing notoginseng and rhodiola root for cardio-cerebral blood vessel diseases and its preparing method | |
| CN1221280C (en) | Chinese patent drug for treating heart brain blood vessel disease and its preparation method | |
| CN1401365A (en) | Chinese health medicine | |
| CN1557407A (en) | Botanical medicine for preventing and treating arteriosclerosis and regulating blood fat and its processing method | |
| CN1291735C (en) | Chinese medicine drippling pill preparation for promoting blood circulation and removing blood stasis, promoting Qi circulation and rilieving pain | |
| CN101361800A (en) | Traditional Chinese medicine for reducing blood fat and enhancing effect and reducing toxin of statins medicine and preparation method thereof | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1506090A (en) | Rheum emodi wall extract and medicine composition with the extract as active component | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN101062314A (en) | Medicine for curing gout and its preparing method | |
| CN1290566C (en) | Depression treating medicinal formulation and its preparation process | |
| CN1232283C (en) | Chinese drugs for treatment of coronary heart disease and angina pectoris | |
| CN1666658A (en) | Health products adapted for diabetic and production method thereof | |
| CN1682972A (en) | Chinese medicine composition for treating cardiovascular disease and its preparing method | |
| CN107669782A (en) | A kind of Chinese medicinal granule product for reducing blood glucose and preparation method thereof | |
| CN1125595C (en) | Oral composition with cardiovascular health and senility delaying functions | |
| CN1201742C (en) | Hypoglycemic health-care food for diabetes type II; | |
| CN1939405A (en) | Drop pills for treating coronary heart disease and making method thereof | |
| CN1895346A (en) | Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method | |
| CN1316992C (en) | Medicine for treating heart brain embulus disease and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080430 Termination date: 20140119 |